CP 4632

Drug Profile

CP 4632

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Class Anti-ischaemics; Antiplatelets; Vascular disorder therapies
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemia

Most Recent Events

  • 10 Nov 2006 Discontinued - Preclinical for Ischaemia in Japan (unspecified route)
  • 15 Sep 1999 New profile
  • 15 Sep 1999 Preclinical development for Ischaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top